|
Market Closed -
Nasdaq
01:30:00 31/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 69.39 USD | +4.82% |
|
+7.53% | +58.32% |
| 30/10 | RBC Raises Price Target on Exelixis to $58 From $51, Keeps Sector Perform Rating | MT |
| 30/10 | Analyst recommendations: GE Vernova, Intel, Reddit, Caterpillar, Crocs… |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.69TCr | |||||
| 6.38TCr | |||||
| 5.64TCr | |||||
| 5.46TCr | |||||
| 4.41TCr | |||||
| 4.21TCr |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
